Research Laboratory of Translational Oncology

Head of the Laboratory — Maxim Shevtsov.

Specialists of the Laboratory

Leading Researcher Danila Bobkov
Leading Researcher Natalia Yudintseva
Senior Researcher Alexander Kim
Junior Researcher Anastasia Nechaeva
Junior Researcher Ruslana Tagaeva

Major publications

Shevtsov M., Stangl S., Nikolaev B., Yakovleva L., Marchenko Y., Tagaeva R., Sievert W., Pitkin E., Mazur A., Toltoy P., Galibin O., Ryzhov V., Steiger K., Smirnov O., Khachatryan W., Chester K., Multhoff G. Granzyme B functionalized nanoparticles targeting membrane Hsp70-positive tumors for multimodal cancer theranostics. Small. 2019; 15(13):e1900205. WoS IF = 10.856, Q1
Goryaynov S. A., Okhlopkov V. A., Golbin D. A., Chernyshov K. A., Svistov D. V., Martynov B. V., Kim A. V., Byvaltsev V. A., Pavlova G. V., Batalov A., Konovalov N. A., Zelenkov P. V., Loschenov V. B., Potapov A. A. Fluorescence Diagnosis in Neurooncology: Retrospective Analysis of 653 Cases. Front Oncol. 2019;9:830. WoS IF = 4.848, Q1
Shevtsov M., Sato H., Multhoff G., Shibata A. Novel approaches to improve the efficacy of immuno-radiotherapy. Frontiers in Oncology. 2019;9:156. WoS IF = 4.25, Q1
Shevtsov M., Pitkin E., Ischenko A., Stangl S., Khachatryan W., Galibin O., Edmond S., Lobinger D., Multhoff G. Ex vivo Hsp70-activated NK cells in combination with PD-1 inhibition significantly increase overall survival in preclinical models of glioblastoma and lung cancer. Frontiers in Immunology. 2019;10:454. WoS IF = 4.716, Q1
Stangl S., Tei L., De-Rose F., Reder S., Martinelli J., Sievert W., Shevtsov M., Öllinger R., Rad R., Schwaiger M., Alessandria C.D., Multhoff G. Preclinical evaluation of the Hsp70 peptide tracer TPP-PEG24-DFO[89Zr] for tumor-specific PET/CT imaging. Cancer Research. 2018;78(21):6268-628. WoS IF = 8.378, Q1
Shevtsov M., Nikolaev B., Marchenko Y., Yakovleva L., Skvorzov N., Mazur A., Tolstoy P., Ryzhov V., Multhoff G. Targeting experimental glioblastoma with chitosan-based superparamagnetic iron oxide nanoparticles (CS-DX-SPIONs). International Journal of Nanomedicine. 2018;13:1471-1482. WoS IF = 4.471, Q1
Stangl S., Tontcheva N., Sievert W., Shevtsov M., Niu M., Schmid T. E., Pigorsch S., Combs S. E., Haller B., Balermpas P., Rödel F., Rödel C., Fokas E., Krause M., Linge A., Lohhaus F., Baumann M., Tinhofer I., Budach V., Stuschke M., Grosu A.L., Abdollahi A., Debus J., Belka C., Maihöfer C., Mönnich D., Zips D., Multhoff G. Heat shock protein 70 and tumor-infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). International Journal of Cancer. 2018;142(9):1911-1925. WoS IF = 4.982, Q1
Shevtsov M. A., Parr M. A., Ryzhov V. A., Zemtsova E. G., Ponomareva A. N., Smirnov V. M., Multhoff G. Zero-valent Fe confined mesoporous silica nanoparticles (Fe(0)@MCM-41) for targeting experimental orthotopic glioma in rats. Scientific Reports. 2016;6:29247. WoS IF = 4.011, Q1

Contacts

Maxim Shevtsov, Head of the Laboratory
Tel.: +79217924009
е-mail: shevtsov-max@mail.ru